Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 12, 2010

Agilent to Use Caliper Microfluidic Chips for Seven More Years

  • Agilent Technologies renewed its supply arrangement for microfluidics chips from Caliper Life Sciences. Caliper will continue to be the exclusive supplier of chips used in Agilent's Bioanalyzer 2100 platform for the next seven years.

    “Agilent's success with the Bioanalyzer over the past decade affirms the importance of Caliper's microfluidics technologies to life sciences,” notes Kevin Hrusovsky, president and CEO of Caliper. 

    “Agilent represents our largest OEM customer and accounted for over 15% of our total microfluidics business in 2009. 

    “We expect our microfluidics business to grow 10–15% in 2010, and the renewal of this relationship with its improved economics is a vital element of our strategy for sustainable double-digit growth in our microfluidics franchise over the long term,” Hrusovsky continues. “We believe that our microfluidics technologies will continue growing as a critical tool for sample analysis as well as for sample preparation, particularly as sequencing and gene-expression workflows become fundamental to the realization of personalized medicine.”

    Since its introduction in 1999, Agilent has reportedly sold over 7,000 Bioanalyzer 2100 instruments worldwide. Caliper says that it has supplied approximately 5 million chips for use on these instruments. The company owns or exclusively licenses a portfolio of over 400 issued U.S. patents in the field of microfluidics.


Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »